Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.68 USD | -2.69% | -5.65% | -4.57% |
02/04 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
29/03 | KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.57% | 19.33M | |
+31.37% | 588B | |
-2.81% | 364B | |
+20.37% | 326B | |
+5.47% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.87% | 167B | |
+0.12% | 161B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Kala Pharmaceuticals : Oppenheimer Adjusts Kala Pharmaceuticals PT to $13 From $15, Maintains Outperform Rating